BOSTON, Jan. 22, 2018 /PRNewswire/ -- BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the Company's leading product...
from PR Newswire: //http://ift.tt/2Dr5KeI
No comments:
Post a Comment